Articles On Universal Biosensors Inc (ASX:UBI)

Perversely, Polynovo stands to benefit from a US reimbursement cut for outpatients ASX biotechs had a poor August, but they will Spring into action Race Oncology opens Hong Kong site in “cautious” trial rollout   PolyNovo (ASX:PNV) shares...

Artrya shares surge up to 42% on FDA clearance of the company’s Salix Coronary Plaque device Sonic Healthcare joins CSL in the healthcare sin bin Universal Biosensors calls in the corporate undertakers   Artrya (ASX:AYA) has won US Food a...

ASX shifts gears around 11am to lift 0.25pc by end of trade Banks, discretionary and real estate lead gains Materials drags as James Hardie dives   ASX settles back into green Earnings season is making for a bit of a seesaw on the ASX thi...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

 Audeara and Ear Science Institute Australia will strive to develop a more affordable bone-conduction hearing device Auditor voices “substantial doubt” over Universal Biosensors’ viability Freeze a jolly good fellow: Brent Owens take over...

Bioxyne stars with a 720% gain in the 2024-25 year Paradigm shares soar 34% after $41 million convertible note deal Biotechs turn to debt funding The ASX biotech sector’s best EOFY performer has come from left field: the local and Europ...

Markets pricing a 78pc chance of rate cut following labour data Unemployment levels remained steady ASX dips on broad weakness in tech, resources and healthcare stocks   The ASX ended up in negative territory this afternoon, but not by mu...

Highlights ASX 200 marked a new short-term high, driven by gains in gold and banking sectors Key miners including EPM and NC1 announced significant exploration updates Broader market sentiment remained positive across most s...

By stockpiling components, the US-focused Impedimed is taking no chances with tariffs Cashed-up Amplia forges ahead with promising pancreatic cancer trial Some biotechs are headed to the well, while others are rolling in the green stuff...

Universal Biosensors (ASX:UBI) is well into commercial phase and is thus ‘grown up’, but chairman Graham McLean acknowledges the company has struggled to reach adulthood and produce consistent returns. “Progress has always been slower than...

The winds of CEO change bloweth through the early commercial-stage end of the market Trial news from Neurizon and Blinklab Opthea’s latest setback brings perversely good news   The long-standing CEOs of two early commercial stage biotech...

Despite the current political upheaval, the US health sector remains the first port of call for most biotechs FDA approvals have sparked one-day share surges of as much as 500% Several ASX companies await do-or-die FDA approvals Despite r...

Universal Biosensors (ASX:UBI) shares were flat on Friday, even as the microcap healthcare company inked a US distribution deal for its blood monitoring sensors. UBI’s Xprecia Prime device is a portable handheld device used to analyse p...

The ASX200 spiked straight after the Reserve Bank of Australia announced it’ll hold interest rates at 4.35 per cent – the index closing up more than a third (0.36) of a per cent. As far as how sectors went – Materials and Energy each add...

Global electrochemical cell technology company, Universal Biosensors (ASX:UBI) shares have surged 60% following the attainment of US Food and Drug Administration (FDA) and Clinical Laboratory Improvement Amendments (CLIA) Waiver approvals f...

Melbourne-based medical company Universal Biosensors (ASX: UBI) has received two approvals from the US Food and Drug Administration (FDA) for its Xprecia Prime coagulation analyser as a class II device. Receipt of FDA 510(k) and a clinical...

Universal Biosensors, Inc (ASX: UBI) shares are having a day to remember on Tuesday. At the time of writing, the ASX healthcare stock is up 72% to 27.5 cents. Why is this ASX healthcare stock jumping? Investors have been fighting to get ho...

The ASX is set to open slightly lower on Wednesday Wall Street fell after Moody’s downgraded US regional banks Hong Kong issues new crypto exchange licences   The ASX is set to open slightly lower on Wednesday amid new concerns about the...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Local shares to snap losing streak and open higher Berkshire Hathaway jumped 3.5% to a record high DNR Capital says now is the time to buy small caps   The ASX 200 is set to open higher on Tuesday, bolstered by gains in New York after a f...

Diabetes drug Canagliflozin lowers Proteomics’ PromarkerD diabetic prediction scores Artrya says Q-Submission (Q-Sub) has now been lodged with the FDA Universal Bio launched the PETRACKR blood glucose monitoring product for pets   Protemi...

Universal Biosensors (UBI) launches PETRACKR, a blood glucose monitoring product for dogs and cats with diabetes, globally In tandem with the launch, UBI has signed three distribution deals across the US and Canada The company has rec...

The ASX will open lower this morning after a 1% fall on Wall Street US regional bank stocks tumbled again Oil prices crashed around 5% on recession fears   The ASX is poised to tumble on Wednesday, tracking the moves in New York. At 8am A...

Universal Biosensors (UBI) submits a 510K application to the US FDA for approval to sell Xprecia Prime in the United States The application included UBI’s patient study which provided clinical evidence of its portable coagulation monito...

Universal Biosensors (UBI) launches its acetic acid biosensor test on the Sentia wine testing platform This marks the fifth test available on the platform, with “ideal” timing for the upcoming fermentation and maturation period for north...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Universal Biosensors (UBI) recruits the last patient for its prothrombin time (PT/INR) blood coagulation clinical study The study will provide clinical evidence on the performance of UBI’s Xprecia Prime coagulation device Universal Bi...

Universal Bio completes patient recruiting for Xprecia Prime study Neuren Pharma given approval by FDA to start Phase 2 trial Chimeric completes Phase 1A trial with flying colours   Universal Bio to lodge FDA submission this quarter Unive...

Tim Boreham is one of Australia’s best-known small-cap share analysts and business journalists. He has more than 30 years of experience writing for major business publications.   After a rickety year dominated by the interest rate rises we...

UBI will have its work published on the front cover of respected publication Neurotech gets green light for Phase II/III trial Sonic Healthcare’s revenue disappoints UBI’s work gets published Universal Biosensors (ASX:UBI) rose 6% this mo...

Biosensor developer Universal Biosensors [ASX:UBI] spiked on Tuesday after delivering a market update. The post Universal Biosensors [ASX:UBI] Spikes 16% appeared first on Money Morning Australia.

The ASX healthcare sector rebounds on back of $20 billion Ramsay Healthcare takeover bid Volpara founder and CEO steps into new role as female CEO takes the reins Medlab Clinical shares soar after UK trade deal for probiotic for patients...

Medical diagnostics company Universal Biosensors (UBI) raises $6 million via an institutional placement of new CHESS depositary interests (CDIs) The funds were raised through the issue of almost 7.8 million CDIs at 77 cents, a five per cen...

Universal Biosensors (UBI) is aiming to raise about $25 million to fund new product development, working capital, and manufacturing capability It will issue new shares at 77 cents each through an entitlement offer and a placement The entit...

ASX posts steady gains on Tuesday Activity stays strong in the small cap resources space US stocks futures pointing ~0.3% higher Local stocks shrugged off the post-Easter food coma with solid gains on Tuesday — a calm session in what’s be...

Healthcare and life sciences expert Scott Power,who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. The Australian Open has kicked o...

The ASX 200 posted a small 0.11 fall on Tuesday, outperformed by the small end of town as the microcap Emerging Companies index rose by 0.66%. There were no clear catalysts as Asian markets struggled for direction after Wall Street was clos...

Highlights UBI launches Sentia Malic Acid Test into the international wine market. The first delivery and sales of the Sentia Malic Acid Test are scheduled for late January 2022 into the USA, Australia, and New Zealand markets. The co...

Highlights Penny stocks are shares which trade at a price lower than AU$5 Penny stocks are inexpensive to buy and good for those investors looking to start on a low budget. HLA, EMD and UBI are three healthcare penny stocks under disc...

Highlights  A bunch of COVID-19 variants, especially Delta and Omicron, are surging to post record numbers worldwide. According to the WHO, one should avoid crowded and confined places as well as close contact settings. Getting vaccin...

24 Dec 2021 - Medical diagnostic company Universal Biosensors (ASX:UBI) has agreed to be in an exclusive contract with IQ Science to scale a Covid-19 detection test that gives resu…

Universal Biosensors (UBI) has entered into a global exclusive licence agreement with IQ Science for commercialisation of a SARS-CoV-2 N-Protein detection test The COVID-19 test will utilise UBI’s proprietary electrochemical strip and devi...

24 Dec 2021 - A snapshot of the stocks on the move featuring AMP (ASX:AMP), Universal Biosensors (ASX:UBI), and Family Zone Cyber Safety (ASX:FZO).

The Universal Biosensors Inc (ASX: UBI) share price is in the green after the company announced a licensing deal to commercialise a new rapid COVID-19 test. Shares in the biotech are swapping hands for 89 cents at the time of writing, up 0...

The ASX 200 Health Index (XHJ) is trading higher by 0.70% at the time of writing, compared to the broader index which is up by 0.55%. OncoSil Medical (ASX:OSL) has released the final results of the PanCO clinical study for the treatment of...

Universal Biosensors (UBI) enters into a collaboration agreement with Mayo Clinic Biopharma Diagnostics Mayo Clinic is one of the world’s most prestigious oncology research and treatment institutions The agreement covers multiple projects...

The ASX 200 Health Index (XHJ) is down by 1.0% at the time of writing, compared to the broader index which is down by 0.1%. Medical diagnostics company, Universal Biosensors (ASX:UBI), has entered into a collaboration agreement with Mayo Cl...

Wall Street falls as US inflation hits 30-year high US stocks continued their slide overnight, as the latest data showed that consumer prices rose at a pace not seen since the early 1990s. Prices in the US jumped 0.9% in October, and 6.2% f...

The ASX 200 Health Index (XHJ) is up by 0.80% at the time of writing, compared to the broader index which is higher by 0.7%. Notices from both the Australian and European Patent Offices have been received by Noxopharm (ASX:NOX), relating to...

Linius pursues commercialisation of video virtualisation engine tech UBI up after nabbing new distribution deal for its Sentia wine product Keypath unchanged 40.8% revenue increase to US$30.4 million   Linius Technologies (ASX:LNU) Cloud...